The European Patent Office (EPO) has published patent application EP2026030628A2, titled 'TARGET, BIOMARKER, AND PATIENT SELECTION DISCOVERY METHODS USING CELL-TYPE SPECIFIC SPATIAL PROTEOMICS AND MACHINE LEARNING'. This publication relates to novel methods for identifying targets, biomarkers, and patient populations in drug discovery, leveraging advanced proteomics and machine learning techniques. The application was published on March 18, 2026, and covers designated states within the European Union.

This patent application represents an advancement in the field of biotechnology and drug development. While it does not impose immediate compliance obligations, it is relevant for companies involved in pharmaceutical research and development, particularly those utilizing AI and proteomic data. Compliance officers in the pharmaceutical sector should be aware of this publication as it may influence future intellectual property strategies and research directions within the industry.